H.C. Wainwright lowered the firm’s price target on Orchestra BioMed (OBIO) to $12 from $14 and keeps a Buy rating on the shares following the Q4 report. Discover the latest stocks recommended by ...

Orchestra BioMed (NASDAQ:OBIO – Get Free Report) had its price objective decreased by analysts at HC Wainwright from $14.00 to $12.00 in a research note issued on Friday,Benzinga reports.